grapesharvester schreef op 18 april 2012 13:44:
De laatste tijd loopt koer van Morphosys op. vandaag naar EUR 22.50
voreger schommelde de koers rond EUR 18 samen met crucell.
Het lijkt er op dat dit samenhangt met een op 2 april gestart aandeleninkoop programma.
vandaag nieuwe commissarissen benoemd:
MorphoSys Nominates Karin Eastham and Marc Cluzel as New Supervisory Board Members
.
April 18, 2012 / 7:30 am, CET
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the Company will nominate Ms. Karin Eastham and Dr. Marc Cluzel as new members of the Supervisory Board at the Company's Annual Shareholder Meeting on Thursday, May 31, 2012. Ms. Eastham and Dr. Cluzel will replace Prof. Dr. Jürgen Drews and Dr. Metin Colpan. Prof. Drews has been a member of MorphoSys AG's Supervisory Board since 1998, while Dr. Colpan joined in 2004.
"We are delighted to be able to present two highly qualified candidates for MorphoSys's Supervisory Board," commented Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG. "Karin Eastham and Marc Cluzel both have outstanding track records in our industry and have contributed to the successful performance of several companies over the course of their careers."
Karin Eastham is an experienced financial executive who currently serves as director on the Corporate Boards of Illumina, Inc., Amylin, Inc., Trius Therapeutics, Inc. and Geron Corporation. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer and as a member of the Board of Trustees of the Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation. She previously held similar positions with CombiChem, Inc. and Cytel Corporation. She also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S. and a M.B.A. from Indiana University and is a Certified Public Accountant.
Dr. Marc Cluzel, an established innovator and leader in the pharmaceutical industry, has more than 20 years of extensive knowledge and experience in Research & Development and product registration in the USA, Europe and Japan. Dr. Cluzel founded C&F consulting in 2011 and serves also as Executive Vice President of Product Development at HÙYÀ Bioscience International, LLC. Dr. Cluzel served as global head of R&D for Sanofi from 2007 to 2011, as Executive Vice President of Research & Development for Sanofi (Formerly Sanofi-Aventis SA) and before 2009 as its Senior Vice President of Science and Medical Affairs. He was also since 2002 chairman and CEO of Sanofi-Synthelabo R&D France then Sanofi-Aventis R&D France. His career began in hospital medical care and gradually transitioned to research at Johns Hopkins University, Baltimore and Guy's Hospital, London. Dr. Cluzel holds both an MD and a PhD from the University of Montpellier, France.